Corona Remedies IPO: Investors Flock as 262 Profit Per Share Looms

• Corona Remedies IPO opened December 8, closing December 10, aiming to raise Rs 655.37 crore via an Offer for Sale.
• The IPO was subscribed 2.72 times overall by December 10, with non-institutional investors leading at 5.89 times.
• Shares are priced between Rs 1,008 and Rs 1,062, with a lot size of 14 shares.
• Grey Market Premium (GMP) indicates a potential listing gain of 24%, with shares trading at a Rs 262 premium.
• Analysts from Arihant Capital and SBI Securities recommend 'Subscribe' due to strong growth potential and fair valuation.

Why It Matters: Investors can gain quick profits from this IPO's strong market premium.